The U.K. government has recently announced their plans for a new U.K. Life Sciences Super Cluster - a scheme where industry, academia and the National Health Service work together to deliver new treatments for chronic disease. The pilot project is being supported by a £1 Million investment from the government and the first Super Cluster will launch later this year in the area of immunology and inflammation, focusing on diseases such as asthma and rheumatoid arthritis.

The U.K. Life Sciences industry employs over 120,000 people and invests approximately £4.6 billion into R&D. The unveiling of this new scheme comes in addition to recent measures to help the U.K. maintain a competitive edge in translational medicine, including the Patent box and Innovation Pass initiatives, to better compete on a global stage and attract inward investment.

More detailed information can be accessed at the following website and the blueprint documents which may be found there: